share_log
Breakings ·  Jun 26 20:00
Brainstorm Cell Therapeutics Reaches Alignment With FDA on Cmc Aspects of Phase 3B Nurown® Clinical Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment